For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Atossa Genetics Inc. is a member of the Medical sector. This group includes 1026 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atossa Genetics Inc. is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for ATOS' full-year earnings has moved 16.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Based on the most recent data, ATOS has returned 36.4% so far this year. In comparison, Medical companies have returned an average of 5.8%. This means that Atossa Genetics Inc. is outperforming the sector as a whole this year. One other Medical stock that has outperformed the sector so far this year is Hologic (HOLX). The stock is up 6.1% year-to-date. Over the past three months, Hologic's consensus EPS estimate for the current year has increased 1.4%. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Atossa Genetics Inc. is a member of the Medical - Instruments industry, which includes 86 individual companies and currently sits at #153 in the Zacks Industry Rank. On average, this group has gained an average of 3.9% so far this year, meaning that ATOS is performing better in terms of year-to-date returns. Hologic is also part of the same industry. Going forward, investors interested in Medical stocks should continue to pay close attention to Atossa Genetics Inc. and Hologic as they could maintain their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Atossa Genetics Inc. (ATOS):Free Stock Analysis Report Hologic, Inc. (HOLX):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...